Skip to main content
Equibles
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc · Investor Relations

Track IRWD — free

Use IRWD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRWD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.64 -0.12 (-3.19%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$682.44M
Shares
165.24M
Volume · Oct 2 2.7M Avg daily vol (3M) 2.12M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-07-14 Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
2026-05-28 Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
2026-05-27 FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
2026-05-07 Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
2026-05-04 Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
2026-04-30 Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
2026-04-23 Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
2026-03-04 Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2026-02-25 Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
2026-02-18 Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
2026-01-02 Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
2025-11-10 Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
2025-08-07 Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
2025-05-07 Ironwood Pharmaceuticals Reports First Quarter 2025 Results
2025-04-30 Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2025-04-25 Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
2025-04-22 Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
2025-04-14 Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
2025-03-27 Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
2025-02-27 Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
2025-02-20 Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
2025-01-29 Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
2024-11-26 Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
2024-11-13 Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
2024-11-07 Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Past events

Date Event Type
2026-06-04 Jefferies Global Healthcare Conference Conference
2026-05-07 Ironwood Pharmaceuticals Q1 2026 Investor Update Conference Call Earnings call
2026-03-11 The Citizens Life Sciences Conference Conference
2026-02-25 Ironwood Pharmaceuticals Q4 and Full Year 2025 Investor Update Conference Call Earnings call
2025-05-07 The Citizens Life Sciences Conference Conference
2025-02-27 Ironwood Pharmaceuticals Q4 and Full Year 2024 Investor Update Conference Call Earnings call
2025-01-29 Ironwood Pharmaceuticals Corporate Update Event
2024-12-04 Piper Sandler 36th Annual Healthcare Conference Conference
2024-11-20 Jefferies London Healthcare Conference Conference
2024-11-07 Ironwood Pharmaceuticals Q3 2024 Investor Update Conference Call Earnings call
2024-10-29 ACG Oral Presentation of STARS Subgroup Analyses by Baseline Demographics and SBS Disease Characteristics Presentation
2024-09-05 2024 Wells Fargo Healthcare Conference Conference
2024-08-08 Ironwood Pharmaceuticals Q2 2024 Investor Update Conference Call Earnings call
2024-06-06 Jefferies Global Healthcare Conference Conference
2024-05-21 Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Presentation
2024-05-13 The Citizens JMP Life Sciences Conference Conference
2024-05-09 Ironwood Pharmaceuticals Q1 2024 Investor Update Conference Call Earnings call
2024-02-29 STARS Phase 3 Positive Topline Results Conference Call Earnings call
2024-02-15 Ironwood Pharmaceuticals Q4 and Full Year 2023 Investor Update Conference Call Earnings call
2024-01-10 42nd Annual J.P. Morgan Healthcare Conference Conference
2023-11-29 Piper Sandler 35th Annual Healthcare Conference Conference
2023-11-09 Ironwood Pharmaceuticals Q3 2023 Investor Update Conference Call Earnings call
2023-08-08 Ironwood Pharmaceuticals Q2 2023 Investor Update Conference Call Earnings call
2023-05-22 Ironwood Announces Agreement to Acquire VectivBio Event
2023-05-16 The JMP Securities Life Sciences Conference Conference

Source: https://investor.ironwoodpharma.com/home/default.aspx

Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 4 filings 4 filers Visit website Investor relations